FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014751188> ?p ?o ?g. }

• W2014751188 endingPage "60" @default.
• W2014751188 startingPage "53" @default.
• W2014751188 abstract "Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC).To evaluate enzalutamide's effects on cancer and on androgens in blood and bone marrow, and associate these with clinical observations.In this prospective phase 2 study, 60 patients with bone mCRPC received enzalutamide 160mg orally daily and had transilial bone marrow biopsies before treatment and at 8 wk of treatment.Androgen signaling components (androgen receptor [AR], AR splice variant 7 (ARV7), v-ets avian erythroblastosis virus E26 oncogene homolog [ERG], cytochrome P450, family 17, subfamily A, polypeptide 1 [CYP17]) and molecules implicated in mCRPC progression (phospho-Met, phospho-Src, glucocorticoid receptor, Ki67) were assessed by immunohistochemistry; testosterone, cortisol, and androstenedione concentrations were assessed by liquid chromatography-tandem mass spectrometry; AR copy number was assessed by real-time polymerase chain reaction. Descriptive statistics were applied.Median time to treatment discontinuation was 22 wk (95% confidence interval, 19.9-29.6). Twenty-two (37%) patients exhibited primary resistance to enzalutamide, discontinuing treatment within 4 mo. Maximal prostate-specific antigen (PSA) decline ≥ 50% and ≥ 90% occurred in 27 (45%) and 13 (22%) patients, respectively. Following 8 wk of treatment, bone marrow and circulating testosterone levels increased. Pretreatment tumor nuclear AR overexpression (> 75%) and CYP17 (> 10%) expression were associated with benefit (p = 0.018). AR subcellular localization shift from the nucleus was confirmed in eight paired samples (with PSA decline) of 23 evaluable paired samples. Presence of an ARV7 variant was associated with primary resistance to enzalutamide (p = 0.018). Limited patient numbers warrant further validation.The observed subcellular shift of AR from the nucleus and increased testosterone concentration provide the first evidence in humans that enzalutamide suppresses AR signaling while inducing an adaptive feedback. Persistent androgen signaling in mCRPC was predictive of benefit and ARV7 was associated with primary resistance.We report a first bone biopsy study in metastatic prostate cancer in humans that searched for predictors of outcome of enzalutamide therapy. Benefit is linked to a pretreatment androgen-signaling signature.ClinicalTrials.gov identifier NCT01091103." @default.
• W2014751188 created "2016-06-24" @default.
• W2014751188 creator A5008820123 @default.
• W2014751188 creator A5009388082 @default.
• W2014751188 creator A5021008372 @default.
• W2014751188 creator A5021183845 @default.
• W2014751188 creator A5024730039 @default.
• W2014751188 creator A5035962068 @default.
• W2014751188 creator A5036272242 @default.
• W2014751188 creator A5040146877 @default.
• W2014751188 creator A5062011968 @default.
• W2014751188 creator A5074919849 @default.
• W2014751188 creator A5078910130 @default.
• W2014751188 date "2015-01-01" @default.
• W2014751188 modified "2023-10-01" @default.
• W2014751188 title "Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer" @default.
• W2014751188 cites W1965002585 @default.
• W2014751188 cites W1967789049 @default.
• W2014751188 cites W1980244461 @default.
• W2014751188 cites W2004905634 @default.
• W2014751188 cites W2018307268 @default.
• W2014751188 cites W2037700362 @default.
• W2014751188 cites W2039652432 @default.
• W2014751188 cites W2041654131 @default.
• W2014751188 cites W2059535338 @default.
• W2014751188 cites W2077301757 @default.
• W2014751188 cites W2077438659 @default.
• W2014751188 cites W2080134152 @default.
• W2014751188 cites W2080748037 @default.
• W2014751188 cites W2103545212 @default.
• W2014751188 cites W2110534364 @default.
• W2014751188 cites W2110841612 @default.
• W2014751188 cites W2112730174 @default.
• W2014751188 cites W2119504728 @default.
• W2014751188 cites W2121846636 @default.
• W2014751188 cites W2137467802 @default.
• W2014751188 cites W2139711232 @default.
• W2014751188 cites W2140855177 @default.
• W2014751188 cites W2145847071 @default.
• W2014751188 cites W2148643283 @default.
• W2014751188 cites W2150609534 @default.
• W2014751188 cites W2157674746 @default.
• W2014751188 cites W2165782799 @default.
• W2014751188 cites W2167331614 @default.
• W2014751188 doi "https://doi.org/10.1016/j.eururo.2014.05.005" @default.
• W2014751188 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4247811" @default.
• W2014751188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24882673" @default.
• W2014751188 hasPublicationYear "2015" @default.
• W2014751188 type Work @default.
• W2014751188 sameAs 2014751188 @default.
• W2014751188 citedByCount "205" @default.
• W2014751188 countsByYear W20147511882014 @default.
• W2014751188 countsByYear W20147511882015 @default.
• W2014751188 countsByYear W20147511882016 @default.
• W2014751188 countsByYear W20147511882017 @default.
• W2014751188 countsByYear W20147511882018 @default.
• W2014751188 countsByYear W20147511882019 @default.
• W2014751188 countsByYear W20147511882020 @default.
• W2014751188 countsByYear W20147511882021 @default.
• W2014751188 countsByYear W20147511882022 @default.
• W2014751188 countsByYear W20147511882023 @default.
• W2014751188 crossrefType "journal-article" @default.
• W2014751188 hasAuthorship W2014751188A5008820123 @default.
• W2014751188 hasAuthorship W2014751188A5009388082 @default.
• W2014751188 hasAuthorship W2014751188A5021008372 @default.
• W2014751188 hasAuthorship W2014751188A5021183845 @default.
• W2014751188 hasAuthorship W2014751188A5024730039 @default.
• W2014751188 hasAuthorship W2014751188A5035962068 @default.
• W2014751188 hasAuthorship W2014751188A5036272242 @default.
• W2014751188 hasAuthorship W2014751188A5040146877 @default.
• W2014751188 hasAuthorship W2014751188A5062011968 @default.
• W2014751188 hasAuthorship W2014751188A5074919849 @default.
• W2014751188 hasAuthorship W2014751188A5078910130 @default.
• W2014751188 hasBestOaLocation W20147511882 @default.
• W2014751188 hasConcept C121608353 @default.
• W2014751188 hasConcept C126322002 @default.
• W2014751188 hasConcept C126894567 @default.
• W2014751188 hasConcept C134018914 @default.
• W2014751188 hasConcept C143998085 @default.
• W2014751188 hasConcept C2776235491 @default.
• W2014751188 hasConcept C2776551883 @default.
• W2014751188 hasConcept C2777911890 @default.
• W2014751188 hasConcept C2780007613 @default.
• W2014751188 hasConcept C2780192828 @default.
• W2014751188 hasConcept C502942594 @default.
• W2014751188 hasConcept C61367390 @default.
• W2014751188 hasConcept C71315377 @default.
• W2014751188 hasConcept C71924100 @default.
• W2014751188 hasConceptScore W2014751188C121608353 @default.
• W2014751188 hasConceptScore W2014751188C126322002 @default.
• W2014751188 hasConceptScore W2014751188C126894567 @default.
• W2014751188 hasConceptScore W2014751188C134018914 @default.
• W2014751188 hasConceptScore W2014751188C143998085 @default.
• W2014751188 hasConceptScore W2014751188C2776235491 @default.
• W2014751188 hasConceptScore W2014751188C2776551883 @default.
• W2014751188 hasConceptScore W2014751188C2777911890 @default.
• W2014751188 hasConceptScore W2014751188C2780007613 @default.
• W2014751188 hasConceptScore W2014751188C2780192828 @default.

• next